
usd jul pm et
summari compani global research-bas pharmaceut busi key drug
humira rheumatoid arthriti indic
price-to-earnings oper ep
heavili reliant one drug humira
current account sale howev
recently-approv drug like help diversifi sale
past perform indic futur perform reli upon
analysi prepar equiti analyst
jun stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
lift target
base price-to-earnings multipl
combin compani
ep estim ep vs
surpass consensu expect
lift ep
maintain stand-alone ep
sale declin billion
expect due
higher-than-expect sale skyrizi
humira outsid ou ou sale
humira continu face biosimilar
expect declin meanwhil
 sale humira expand
billion in-lin expect skyrizi
sale launch may reach
million world-wide expect skyrizi
sale exceed million back half
initi expect sale
million anticip posit fda
decis come week drug
upadacitinib rheumatoid arthriti /kevin
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview global research-bas biopharmaceut compani
develop market advanc therapi address world complex seriou
diseas product focus treat condit chronic autoimmun diseas
rheumatolog gastroenterolog dermatolog oncolog includ blood cancer virolog includ
hepat viru hcv human immunodefici viru hiv neurolog disord
parkinson diseas metabol diseas includ thyroid diseas complic associ
cystic fibrosi pain associ endometriosi well seriou health condit also
pipelin promis new medicin clinic develop across import medic
specialti immunolog oncolog neurosci addit target invest cystic
fibrosi women health
abbv largest success drug humira approv treat autoimmun diseas
 canada mexico european union humira also sold mani market world-wide
drug account approxim abbv total net revenu humira began
experi biosimilar competit countri outsid ou ou sale account
approxim global humira revenu expect encount biosimilar competit
humira begin possibl earlier anticip entranc biosimilar competit
corpor strategi abbv strategi focus deliv strong financi result advanc
invest pipelin return valu sharehold ensur strong sustain growth
busi long term expect achiev strateg object
hematolog oncolog revenu growth imbruvica venclexta strong execut new
product launch across multipl therapeut area humira sale growth drive biolog
penetr across diseas categori maintain market leadership effect manag
humira intern biosimilar eros favor impact pipelin product indic
recent approv current regulatori review approv expect
pipelin accord abbv form compani compound indic
clinic develop focu immunolog oncolog neurosci abbv program
mid- late-stag develop
financi trend abbv revenu billion increas prior-year period
repres five-year compound annual growth rate compound-annual-growth-rate top-lin growth
larg driven revenu growth relat mavyret imbruvica venclexta continu
strength humira adjust earn per share ep grew year-over-year
repres five-year compound-annual-growth-rate abbv net debt total capit seem high
compani leverag net debt trailing-twelve-month ebitda concern addit
gener billion free cash flow increas prior year
oper
vice chairman extern
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc june technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit outlook biotechnolog
histor defens sub-industri
expect see commerci
develop mani new innov therapi
declin preval patent
expir biotechnolog
compani trade discount
market think remedi
robust pipelin new drug brought
market fda approv novel drug increas
shatter
previou record sinc novel
approv set think mani
drug either newly-approv
late-stag clinic trial consider
commerci prospect repres major
advanc therapi diseas
sclerosi cancer
pace deal slower
mega-d announc
acquisit celgen celg
acquisit botox manufactur
allergan industri debt level
still low risen last five year
cheap see sever matur
biopharmaceut firm made
mark blockbust drug look
off-set lost revenu expir patent
fail ventur promis late-stag
pipelin addit exampl see gilead
scienc like
acquir expect
interest off-set declin hcv
therapi sale expect engag
 activ make failur
biotechnolog compani low debt level
attract valuat rel
industri make favor
think growth biotechnolog
stock limit recent high
drug price come
heighten scrutini polit
apparatu last year despit
talk lower drug price
seen particularli sever measur taken
legisl regulatori bodi
lower drug price democrat took
hous repres
novemb mid-term elect appear
motiv address drug price
still think suffici impetu
effect signific chang near
futur anoth sourc price pressur
drug manufactur pharmaci benefit
manag pbm health insur
exert influenc drug
prescript price pressur
like increas major pbm merg
major insur cvs-aet ci-esrx
biolog price competit innov
act bpcia grant
exclus period brand biolog maker
sinc brand biolog manufactur
aggress use patent law
commerci leverag delay
commerci biosimilar
maintain market domin longer
result expect biosimilar continu
advanc slowli next sever year
year-to-d june
biotechnolog index risen mere
compar rise valu
 composit index
declin
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra maintain hold opinion share abbvi inc
maintain target base
below-p multipl ep estim see
litig biosimilar risk ep vs lower
estim lift ep lower ep
sale increas oper basi billion slightli
expect outsid us sale humira declin oper
expect due biosimilar competit meanwhil us sale humira
expand billion abbv hematolog oncolog portfolio gener
sale billion repres year-over-year increas
oper basi recent obtain fda approv risankizumab
known skyrizi treatment adult moder sever plaqu
psoriasi also prepar anticip approv commerci
launch upadacitinib rheumatoid arthriti /kevin huang cfa
pm et cfra reiter hold opinion share abbvi inc
maintain target below-p multipl
ep estim see risk relat
litig european biosimilar ep vs
lower estim lower ep initi
ep sale increas organ
billion global net revenu hematolog oncolog portfolio
increas billon larg driven increas
imbruvica global humira sale increas billion
expect stronger-than-expect start biosimilar
competit certain intern market intern humira sale
declin oper humira sale grew
manag continu interest aim pick potenti
product could help off-set expect eros humira sale
analyst research note compani news
pm et cfra maintain hold opinion share abbvi inc
lift target base price-to-earnings multipl
combin compani ep estim ep
vs surpass consensu expect lift
ep maintain stand-alone ep
sale declin billion expect due
higher-than-expect sale skyrizi humira outsid ou
ou sale humira continu face biosimilar competit declin
oper vs expect declin meanwhil
sale humira expand billion in-lin expect
skyrizi sale launch may reach million world-wide
expect skyrizi sale exceed million back half
initi expect sale million anticip
posit fda decis come week drug upadacitinib rheumatoid
et cfra keep hold opinion share abbvi inc
lower target price base price-to-earnings
multipl combin compani ep estim
combin compani ep stand-alone ep estim
account pend allergan acquisit merger provid
diversif benefit deriv revenu one
drug humira could also enhanc product portfolio
commerci strength expertis intern infrastructur howev
combin asset two compani like insuffici view
stave sale earn loss attribut expect
entranc biosimilar competit humira addit combin
compani less near-term capac opportunist bolt-on acquisit
billion debt taken fund transact
reason think make sens lower forward price-to-earnings multipl
pm et cfra keep buy opinion share allergan plc
rais target estim valu
cash share mixtur offer today
announc agreement acquir combin would diversifi away
drug humira revenu creat global
biopharmaceut firm term revenu billion annual sale
deal troubl clear regulatori hurdl view
see much overlap therapeut area would surpris see
struggl gain approv sharehold though
offer materi premium recent share price still
consider rang sever notabl hedg fund acquir
larg stake sever year ago may push lucr offer
regardless think deal ultim close earli
keep buy rate share see attract upsid remain
deal close /colin scarola
et cfra keep hold opinion share abbvi inc
allergan plc announc morn
compani enter definit transact agreement
acquir cash stock transact approxim billion
valu premium transact expect close earli
would creat massiv biopharmaceut compani billion
combin revenu manag expect sharehold see
accret first full year combin compani
achiev annual pre-tax synergi cost reduct billion
year three expect combin compani net debt
approxim billion manag intend reduc
billion continu support dividend growth pipelin
invest combin gener billion free cash flow
enough support combin compani capit
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
